FIB-4 Index: Formula and Interpretation
The FIB-4 index is calculated using the formula: [Age (years) × AST (U/L)] / [Platelet count (10⁹/L) × √ALT (U/L)], and is interpreted using cutoff values of <1.3 to rule out advanced fibrosis and >3.25 to rule in advanced fibrosis 1.
Formula Components
The FIB-4 calculation requires four readily available laboratory values:
- Age in years
- AST (aspartate aminotransferase) in U/L
- ALT (alanine aminotransferase) in U/L
- Platelet count in 10⁹/L
This makes FIB-4 an accessible, inexpensive screening tool that can be calculated from routine laboratory tests without proprietary software 2.
Standard Interpretation for Advanced Fibrosis (≥F3)
The evidence-based cutoff values for detecting advanced fibrosis are:
FIB-4 <1.3: Rules out advanced fibrosis with 90% negative predictive value and 70% sensitivity 1. This lower threshold is optimal for excluding significant disease.
FIB-4 >3.25: Rules in advanced fibrosis with 65% positive predictive value and 97% specificity 1. This higher threshold confirms advanced disease with high certainty.
FIB-4 1.3-3.25: Indeterminate zone requiring additional testing (elastography or biopsy for definitive staging).
Using these dual cutoffs, approximately 71% of patients can be correctly classified without liver biopsy 1.
Alternative Cutoffs by Fibrosis Stage
Recent guideline-level evidence from the 2025 WHO systematic review provides additional context 3:
For Advanced Fibrosis (≥F3):
- FIB-4 >1.45 shows 72.6% sensitivity and 66.9% specificity (16 studies)
- FIB-4 >1.2-1.7 range shows 69.1% sensitivity and 70.5% specificity (40 studies)
The slightly higher 1.45 cutoff may be used as an alternative lower threshold, though the original 1.3 cutoff from the development study remains most validated 1.
Critical Age-Related Caveat
Age significantly distorts FIB-4 interpretation, with diagnostic accuracy and likelihood ratios decreasing as age increases 4. The mean FIB-4 value rises with age in both patients with and without fibrosis, making the test less discriminatory in older adults. This is particularly problematic in patients ≥65 years, where FIB-4 performance deteriorates (AUC 0.64 versus 0.68 in younger patients) 5.
Practical implication: In patients ≥65 years, consider using a higher cutoff (e.g., 1.62 as suggested in recent methotrexate studies) or proceed directly to elastography rather than relying on standard FIB-4 thresholds 5.
Disease-Specific Considerations
While FIB-4 was originally developed for HIV/HCV coinfection 1, it demonstrates reasonable performance across multiple liver disease etiologies:
- MASLD/NAFLD: FIB-4 <1.3 shows pooled sensitivity 0.73 and specificity 0.69; the <1.0 threshold increases specificity to 0.83 but reduces sensitivity to 0.63 6
- Hepatitis B: Performance validated in 2025 WHO guidelines with cutoffs as above 3
- Methotrexate hepatotoxicity: Optimal cutoff of 1.62 in patients <65 years 5
Clinical Algorithm
- Calculate FIB-4 using routine labs at baseline
- If FIB-4 <1.3 (or <1.0 for higher specificity): Advanced fibrosis unlikely, continue routine monitoring
- If FIB-4 >3.25: High probability of advanced fibrosis, proceed to hepatology referral and definitive staging
- If FIB-4 1.3-3.25: Indeterminate—obtain elastography or consider liver biopsy
- If age ≥65 years: Interpret with caution; consider elastography as first-line or use higher age-adjusted cutoffs
Common Pitfalls
- Do not use FIB-4 alone in elderly patients without recognizing reduced accuracy 4
- Do not apply hepatitis C cutoffs universally—optimal thresholds vary by disease etiology 6, 5
- Do not ignore the indeterminate zone—28% of patients fall between cutoffs and require additional testing 1
- Do not use FIB-4 to monitor treatment response—it was developed for cross-sectional screening, not longitudinal assessment